Swedish Study Linked Probiotics to Lower Infant NEC Risks
A study of 4,600 infants found that daily probiotic supplementation reduced rates of necrotizing enterocolitis and death.
Updated on Sept. 30, 2026 in Babies
Live Poll
Do you trust national health agencies to balance safety risks with potentially life-saving medical innovations?
Data from Swedish infants analyzed between 2017 and 2024 showed that probiotic regimens significantly decreased occurrences of necrotizing enterocolitis (NEC) and mortality. While these findings suggest protective benefits for premature infants, the use of such supplements remains a point of regulatory contention globally.
Why it matters
Premature infants have immature intestines that are highly susceptible to NEC, a condition where beneficial bacteria in probiotics may help protect the bowel from pathologic threats. Understanding these outcomes is critical for neonatal care providers evaluating the balance between potential health benefits and safety risks.
The study observed 4,600 infants, finding that 0.6% of those given a regimen of B. infantis, B. lactis, and S. thermophilus developed NEC compared to 2.5% of those without. Death rates were similarly lower at 0.3% for the treatment group versus 1.4%.
The players
American Academy of Pediatrics
This professional association of pediatricians provides clinical guidance and policy statements for the health and safety of infants and children.
Infant Bacterial Therapeutics
This pharmaceutical company is currently developing a probiotic supplement that is under review by the FDA for potential use in neonates.
The details
The probiotic regimen was administered once daily before the fourth day of life and continued until the 34th postmenstrual week. Researchers utilized data from Sweden's national neonatal quality registry to compare outcomes before and after the 2020 recommendation for probiotic use.
Timeline
2017-2024: Data collection period for the Swedish study.
2020: Sweden officially recommended probiotic use for premature infants.
2021: The AAP stated evidence did not support routine probiotic administration.
2023: The FDA issued warnings regarding the risk of probiotic-linked sepsis.
2018-present: Period during which the FDA recorded adverse events.
Roadmap
This research follows the development of probiotic-based interventions that are intended to replace or supplement existing neonatal nutritional standards. The findings contribute to a larger shift in the medical field as regulators weigh experimental trial data against long-term safety concerns.
Parents of premature infants may face different medical practices depending on their country's specific neonatal guidelines and local hospital policies. These findings may influence future discussions between healthcare providers and families regarding nutritional support in the NICU.
The takeaway
While probiotics show promise in reducing severe neonatal complications, they are not universally adopted due to significant regulatory and safety warnings. Families should consult closely with neonatal specialists to understand the specific protocols utilized in their local hospital.
Further reading
For more information on infant health developments, visit the Babies section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust national health agencies to balance safety risks with potentially life-saving medical innovations?
